Gram-negative bacterial infections
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Gram-negative bacterial infections
- Therapeutic area
- Infectious Disease
- gram-negative bacterial infections
- bacterial infection, gram-negative
- bacterial infections, gram negative
- bacterial infections, gram-negative
- bacterial infections, gramme negative
- gram negative bacterial infections
- gram-negative bacterial infection
- gramme negative bacterial infections
- infection, gram-negative bacterial
- infections, gram negative bacterial
- infections, gram-negative bacterial
- infections, gramme negative bacterial
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Unknown
- MONDO ID
- MONDO:0021678
- Parent condition
- MONDO:0005113
Related records
Broader conditions (6)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
Narrower conditions (94)
- Acinetobacter infectious disease
- African tick-bite fever
- Anaplasmataceae infectious disease
- Astrakhan spotted fever
- Asymptomatic neurosyphilis
- Bacillary angiomatosis
- Bacterial meningitis caused by gram-negative bacteria
- Bacteroidaceae infectious disease
- Bacteroides infectious disease
- Bartonellaceae infectious disease
- Bartonellosis
- Bejel
- Bordetella parapertussis infectious disease
- Bordetellosis
- Boutonneuse fever
- Brill-Zinsser disease
- Burkholderia infectious disease
- Cardiovascular syphilis
- Cat-scratch disease
- Cepacia syndrome
Trials (53)
- A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult
- A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
- A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830
- A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
- A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
- An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT
- Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
- Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals
- Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
- Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
- Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
- Comparison of Solid Organ Transplant
- Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB
- Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis
- Early-Onset Sepsis Surveillance Study
Approved drugs (2)
- Cefiderocol sulfate tosylate
- Ertapenem sodium
Drugs in development (10)
- Ancremonam Phase 1
- Apramycin Phase 1
- Avibactam Phase 2
- Aztreonam Phase 2
- Cefiderocol Phase 2
- Meropenem Phase 1
- Nacubactam Phase 1
- Tigecycline Phase 3
- Xeruborbactam Phase 1
- Xeruborbactam sodium Phase 1
Other linked drugs (5)
- Ceftazidime
- Cilastatin
- Imipenem
- Minocycline
- Relebactam